The Effectiveness of Bivalent CAR T-Cell Therapy Targeting EGFR and IL13Rα2 in Treating Recurrent Glioblastoma In recent years, the treatment of recurrent glioblastoma (RGBM) has been continually explored and improved, yet overall survival rates remain less than one year, presenting a significant challenge. The limitations of existing treatments an...